Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,951 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Phase 2 Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

NCT02346890
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Renvela
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of TAS-106 to Treat Head and Neck Cancer

NCT00737360
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
TAS-106
Drug
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Orleans Street, Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Adult Subjects With Uncontrolled Type 2 Diabetes

NCT02317796
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MLR-1023
Drug
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
USA and South Korea, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

NCT03026803
View directory record Official record
Conditions
Liver Cancer, Hepatocellular Cancer
Interventions
Oxaliplatin, Capecitabine
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT00058461
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma
Interventions
ifosfamide, etoposide, rituximab, carboplatin, filgrastim, methotrexate, cytarabine, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

NCT06555783
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

NCT01414205
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Obinutuzumab, Corticosteroids
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.

NCT01555866
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers, Renal Impaired
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

NCT06041256
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction
Interventions
AURN001, Corneal Endothelial Cells, Y27632
Combination Product · Biological · Drug
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00439231
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Georg Aue, M.D.
NIH
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Azixa
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Jun 25, 2026, 8:07 PM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

NCT03063645
View directory record Official record
Conditions
Healthy
Interventions
AC-1202, AC-SD-01 (50 g), AC-SD-01 (75 g)
Drug
Lead sponsor
Cerecin
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jun 25, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Duarte, California • Atlanta, Georgia • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
eltrombopag
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Nyack, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

NCT01511081
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jun 25, 2026, 8:07 PM EDT
Active, not recruiting Phase 2 Interventional

High Dose IL 2 and Entinostat in RCC

NCT03501381
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Interleukin-2
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Boost in Healthy Adults

NCT02586792
View directory record Official record
Conditions
Influenza
Interventions
Monovalent influenza A/H7N9 virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
Interventions
HGF plasmid
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Jun 25, 2026, 8:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136
View directory record Official record
Conditions
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Interventions
S095029, pembrolizumab 200 mg (KEYTRUDA ®)
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Ocala, Florida • Noblesville, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Enrolling by invitation Phase 2 Interventional

Sirolimus for Leigh Syndrome

NCT06843811
View directory record Official record
Conditions
Leigh Syndrome
Interventions
Sirolimus
Drug
Lead sponsor
Matthew Demczko
Other
Eligibility
6 Months to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664
View directory record Official record
Conditions
Melanoma
Interventions
Anti-CD137 (4-1BB) (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jun 25, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

NCT00225173
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Jun 25, 2026, 8:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

NCT04447469
View directory record Official record
Conditions
COVID
Interventions
mavrilimumab, Placebo
Drug · Other
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years and older
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jun 25, 2026, 8:07 PM EDT